{
    "nctId": "NCT02870699",
    "briefTitle": "Efficacy of Evonail\u00ae Solution in the Prevention of Nail Damage Induced by Docetaxel in Patients With Breast Cancer.",
    "officialTitle": "Study of the Effectiveness of the Film-forming Solution Evonail\u00ae Versus Placebo in the Prevention of Nail Damage Induced by Docetaxel in Patients With Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Efficacy of the film-forming solution Evonail\u00ae versus placebo on nail damage",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years old\n* Patient with breast carcinoma\n* Patients treated with adjuvant chemotherapy (FEC + 3 docetaxel +/- Herceptin\u00ae)\n* Patients who have never been treated with taxanes\n* Patients with no nail damage before starting the study\n* ECOG performance \\< 2\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Patient allergic to any of the treatment components\n* Use of film-forming solution, solvents or any other products applied to the fingernails (artificial nails ...) in three weeks before the first of docetaxel treatment\n* Risk of exposure to aggressive factors nail during the study\n* Using refrigerants gloves during chemotherapy treatments\n* Onychophagia\n* Presence of nail disease or a history of nail pathology (infectious and other)\n* Pregnant or breast feeding females\n* Patients whose condition is not compatible with the follow-up study",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}